Mrp4 confers resistance to topotecan and protects the brain from chemotherapy

Molecular and Cellular Biology

Volumn 24, Issue 17, 2004, Pages 7612-7621

  Leggas, Markos ^a   Adachi, Masashi ^a   Scheffer, George L ^b   Sun, Daxi ^a   Wielinga, Peter ^c   Du, Guoqing ^a   Mercer, Kelly E ^a   Zhuang, Yanli ^a   Panetta, John C ^a   Johnston, Brad ^a   Scheper, Rik J ^b   Stewart, Clinton F ^a   Schuetz, John D ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CYTOTOXIN; MULTIDRUG RESISTANCE PROTEIN 4; TOPOTECAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BASOLATERAL MEMBRANE; BRAIN CAPILLARY; BRAIN PROTECTION; BRAIN TISSUE; BRAIN VENTRICLE; CANCER CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CHOROID PLEXUS; CONTROLLED STUDY; DRUG EFFICACY; DRUG PENETRATION; ENDOTHELIUM CELL; EPITHELIUM; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MICRODIALYSIS; MOUSE; MOUSE STRAIN; NONHUMAN; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN; CAPILLARIES; CEREBROVASCULAR CIRCULATION; CHOROID PLEXUS; DRUG RESISTANCE, MULTIPLE; HUMANS; MICE; MICE, KNOCKOUT; MICROCIRCULATION; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; RATS; TOPOTECAN;

ANIMALIA;

EID: 4344632950     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.24.17.7612-7621.2004     Document Type: Article

References (49)

1. Adachi, M., G. Reid, and J. D. Schuetz. 2002. Therapeutic and biological importance of getting nucleotides out of cells: a case for the ABC transporters, MRP4 and 5. Adv. Drug Deliv. Rev. 54:1333-1342.
2. Adachi, M., J. Sampath, L. B. Lan, D. Sun, P. Hargrove, R. Flatley, A. Tatum, M. Z. Edwards, M. Wezeman, L. Matherly, R. Drake, and J. Schuetz. 2002. Expression of MRP4 confers resistance to ganciclovir and compromises bystander cell killing. J. Biol. Chem. 277:38998-39004.
3. 14C]azidothymidine and [2-14C]thymidine in mice. J. Pharmacol. Exp. Ther. 257:479-486.
4. 3H]thymidine incorporation assay. J. Immunol. Methods 170:211-224.
5. Asaba, H., K. Hosoya, H. Takanaga, S. Ohtsuki, E. Tamura, T. Takizawa, and T. Terasaki. 2000. Blood-brain barrier is involved in the efflux transport of a neuroactive steroid, dehydroepiandrosterone sulfate, via organic anion transporting polypeptide 2. J. Neurochem. 75:1907-1916.
6. Beal, S. L., and L. B. Sheiner. 1992. NONMEM users' guide. NONMEM Project Group, University of California, San Francisco, Calif.
7. Borst, P., and R. O. Elferink. 2002. Mammalian ABC transporters in health and disease. Annu. Rev. Biochem. 71:537-592.
8. Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254.
9. Brewster, M. E., K. Raghavan, E. Pop, and N. Bodor. 1994. Enhanced delivery of ganciclovir to the brain through the use of redox targeting. Antimicrob. Agents Chemother. 38:817-823.
10. Carmichael, J., W. G. DeGraff, A. F. Gazdar, J. D. Minna, and J. B. Mitchell. 1987. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 47:936-942.
11. Connolly, L., E. Moran, A. Larkin, G. Scheffer, R. Scheper, B. Sarkadi, M. Kool, and M. Clynes. 2001. A new monoclonal antibody, P2A8(6), that specifically recognizes a novel epitope on the multidrug resistance-associated protein 1 (MRP1), but not on MRP2 nor MRP3. Hybrid. Hybridomics 20:333-341.
12. Dean, M., A. Rzhetsky, and R. Allikmets. 2001. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 11:1156-1166.
13. Gao, B., A. Wenzel, C. Grimm, S. R. Vavricka, D. Benke, P. J. Meier, C. E. Reme. 2002. Localization of organic anion transport protein 2 in the apical region of rat retinal pigment epithelium. Investig. Ophthalmol. Vis. Sci. 43:510-514.
14. Ghersi-Egea, J. F., and N. Strazielle. 2001. Brain drug delivery, drug metabolism, and multidrug resistance at the choroid plexus. Microsc. Res. Tech. 52:83-88.
15. Goehlert, U. G., N. M. Ng Ying Kin, and L. S. Wolfe. 1981. Biosynthesis of prostacyclin in rat cerebral microvessels and the choroid plexus. J. Neurochem. 36:1192-1201.
16. Hing, J. P., S. G. Woolfrey, D. Greenslade, and P. M. Wright. 2001. Analysis of toxicokinetic data using NONMEM: impact of quantification limit and replacement strategies for censored data. J. Pharmacokinet. Pharmacodyn. 28:465-479.
17. Hosoya, K., H. Asaba, and T. Terasaki. 2000. Brain-to-blood efflux transport of estrone-3-sulfate at the blood-brain barrier in rats. Life Sci. 67:2699-2711.
18. Houghton, P. J., P. J. Cheshire, L. Myers, C. F. Stewart, T. W. Synold, and J. A. Houghton. 1992. Evaluation of 9-dimethylaminomethyl-10- hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother. Pharmacol. 31:229-239.
19. Kido, Y., I. Tamai, T. Nakanishi, T. Kagami, I. Hirosawa, Y. Sai, and A. Tsuji. 2002. Evaluation of blood brain barrier transporters by co-culture of brain capillary endothelial cells with astrocytes. Drug Metab. Pharmacokin. 17:34-41.
20. Kitazawa, T., T. Terasaki, H. Suzuki, A. Kakee, and Y. Sugiyama. 1998. Efflux of taurocholic acid across the blood-brain barrier: interaction with cyclic peptides. J. Pharmacol. Exp. Ther. 286:890-895.
21. Kruh, G. D., H. Zeng, P. A. Rea, G. Liu, Z. S. Chen, K. Lee, and M. G. Belinsky. 2001. MRP subfamily transporters and resistance to anticancer agents. J. Bioenerg. Biomembr. 33:493-501.
22. Lai, L., and T. M. Tan. 2002. Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues. Biochem. J. 361:497-503.
23. Lamba, J. K., M. Adachi, D. Sun, J. Tammur, E. G. Schuetz, R. Allikmets, and J. D. Schuetz. 2003. Nonsense mediated decay downregulates conserved alternatively spliced ABCC4 transcripts bearing nonsense codons. Hum. Mol. Genet. 12:99-109.
24. Meijer, D. K., G. J. Hooiveld, A. H. Schinkel, J. E. van Montfoort, M. Haas, D. de Zeeuw, F. Moolenaar, J. W. Smit, and P. J. Meier. 1999. Transport mechanisms for cationic drugs and proteins in kidney, liver and intestine: implication for drug interactions and cell-specific drug delivery. Nephrol. Dial. Transplant. 14(Suppl. 4):1-3.
25. Miller, D. S., S. N. Nobmann, H. Gutmann, M. Toeroek, J. Drewe, and G. Fricker. 2000. Xenobiotic transport across isolated brain microvessels studied by confocal microscopy. Mol. Pharmacol. 58:1357-1367.
26. Mottino, A. D., T. Hoffman, L. Jennes, and M. Vore. 2000. Expression and localization of multidrug resistant protein mrp2 in rat small intestine. J. Pharmacol. Exp. Ther. 293:717-723.
27. Naesens, L., J. Balzarini, and E. De Clercq. 1992. Pharmacokinetics in mice of the anti-retrovirus agent 9-(2-phosphonylmethoxyethyl)adenine. Drug Metab. Dispos. 20:747-752.
28. Pandey, H. P., A. Ram, H. Matsumura, S. Satoh, and O. Hayaishi. 1995. Circadian variations of prostaglandins D2, E2, and F2 alpha in the cerebrospinal fluid of anesthetized rats. Biochem. Biophys. Res. Commun. 213:625-629.
29. Paulusma, C. C., M. J. Kothe, C. T. Bakker, P. J. Bosma, B. van, I., J. van Marle, U. Bolder, G. N. Tytgat, and R. P. Oude Elferink. 2000. Zonal down-regulation and redistribution of the multidrug resistance protein 2 during bile duct ligation in rat liver. Hepatology 31:684-693.
30. Rao, V. V., J. L. Dahlheimer, M. E. Bardgett, A. Z. Snyder, R. A. Finch, A. C. Sartorelli, and D. Piwnica-Worms. 1999. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc. Natl. Acad. Sci. USA 96:3900-3905.
31. Reid, G., P. Wielinga, N. Zelcer, I. van der Heijden, A. Kuil, M. de Haas, J. Wijnholds, and P. Borst. 2003. The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal anti-inflammatory drugs. Proc. Natl. Acad. Sci. USA 100:9244-9249.
32. Rubin, L. L., and J. M. Staddon. 1999. The cell biology of the blood-brain barrier. Annu. Rev. Neurosci. 22:11-28.
33. Samad, T. A., K. A. Moore, A. Sapirstein, S. Billet, A. Allchorne, S. Poole, J. V. Bonventre, and C. J. Woolf. 2001. Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 410:471-475.
34. Sampath, J., M. Adachi, S. Hatse, L. Naesens, J. Balzarini, R. M. Flatley, L. H. Matherly, and J. D. Schuetz. 2002. Role of MRP4 and MRP5 in biology and chemotherapy. AAPS Pharm. Sci. 4:E14.
35. Scheffer, G. L., M. Kool, M. Heijn, M. De Haas, A. C. Pijnenborg, J. Wijnholds, A. van Helvoort, M. C. de Jong, J. H. Hooijberg, C. A. Mol, L. M. van der, J. M. de Vree, d. van, V., R. P. Elferink, P. Borst, and R. J. Scheper. 2000. Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies. Cancer Res. 60:5269-5277.
36. Schinkel, A. H., J. J. Smit, O. van Tellingen, J. H. Beijnen, E. Wagenaar, L. Van Deemter, C. A. Mol, M. A. van der Valk, E. C. Robanus-Maandag, and H. P. te Riele. 1994. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502.
37. Schuetz, J. D., M. C. Connelly, D. Sun, S. G. Paibir, P. M. Flynn, R. V. Srinivas, A. Kumar, and A. Fridland. 1999. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat. Med. 5:1048-1051.
38. Spector, R. 1976. Inhibition of methotrexate transport from cerebrospinal fluid by probenecid. Cancer Treat. Rep. 60:913-916.
39. Stewart, C. F., S. D. Baker, R. L. Heideman, D. Jones, W. R. Crom, and C. B. Pratt. 1994. Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. J. Clin. Oncol. 12:1946-1954.
40. Strazielle, N., and J. F. Ghersi-Egea. 1999. Demonstration of a coupled metabolism-efflux process at the choroid plexus as a mechanism of brain protection toward xenobiotics. J. Neurosci. 19:6275-6289.
41. Sun, H., D. W. Miller, and W. F. Elmquist. 2001. Effect of probenecid on fluorescein transport in the central nervous system using in vitro and in vivo models. Pharm. Res. 18:1542-1549.
42. Tanaka, Y., Y. Abe, A. Tsugu, Y. Takamiya, A. Akatsuka, T. Tsuruo, H. Yamazaki, Y. Ueyama, O. Sato, and N. Tamaoki. 1994. Ultrastructural localization of P-glycoprotein on capillary endothelial cells in human gliomas. Virchows Arch. 425:133-138.
43. Tatsuta, T., M. Naito, T. Oh-hara, I. Sugawara, and T. Tsuruo. 1992. Functional involvement of P-glycoprotein in blood-brain barrier. J. Biol. Chem. 267:20383-20391.
44. van Aubel, R. A., P. H. Smeets, J. G. Peters, R. J. Bindels, and F. G. Russel. 2002. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J. Am. Soc. Nephrol. 13:595-603.
45. Wielinga, P. R., G. Reid, E. E. Challa, d. H. van, I., L. Van Deemter, M. De Haas, C. Mol, A. J. Kuil, E. Groeneveld, J. D. Schuetz, C. Brouwer, R. A. De Abreu, J. Wijnholds, J. H. Beijnen, and P. Borst. 2002. Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells. Mol. Pharmacol. 62:1321-1331.
46. Wijnholds, J., E. C. deLange, G. L. Scheffer, D. J. van den Berg, C. A. Mol, d. van, V., A. H. Schinkel, R. J. Scheper, D. D. Breimer, and P. Borst. 2000. Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J. Clin. Investig. 105:279-285.
47. Zamboni, W. C., A. J. Gajjar, T. D. Mandrell, S. L. Einhaus, M. K. Danks, W. P. Rogers, R. L. Heideman, P. J. Houghton, and C. F. Stewart. 1998. A four-hour topotecan infusion achieves cytotoxic exposure throughout the neuraxis in the nonhuman primate model: implications for treatment of children with metastatic medulloblastoma. Clin. Cancer Res. 4:2537-2544.
48. Zamboni, W. C., P. J. Houghton, R. K. Johnson, J. L. Hulstein, W. R. Crom, P. J. Cheshire, S. K. Hanna, L. B. Richmond, X. Luo, and C. F. Stewart. 1998. Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion. J. Pharmacol. Exp. Ther. 284:89-94.
49. Zelcer, N., G. Reid, P. Wielinga, A. Kuil, I. van der Heijden, J. D. Schuetz, and P. Borst. 2003. Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem. J. 371:361-367.